Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Ish who wrote (7389)	11/5/1998 5:08:00 PM
From: Darrel McPherson	Read Replies (1) \| Respond to of 8116

Well I went ahead and bought my hundred then thought about it and bought 900 more. Of course I sold my hungarian internet stock to do this big purchase and of course the internet stock went up 30% within an hour of me selling it. Is this what you call market timing?

To: Ish who wrote (7389)	11/6/1998 12:57:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

Still bleeding, but improving(?) PR Newswire - November 06, 1998 11:38 ProstaScint(R) Sales Increase Over 30% PRINCETON, N.J., Nov. 6 /PRNewswire/ -- CYTOGEN Corporation (Nasdaq: CYTO) today reported financial results for the third quarter and nine months ended September 30, 1998. For the quarter, the company had a net loss of $3.7 million or $0.06 per share, compared to a net loss of $11.9 million or $0.23 per share for the comparable period in 1997. Total revenue for the third quarter of 1998 was $2.8 million, which does not include $2.8 million recorded as a non-operating gain from the divestiture of Targon Corporation, a CYTOGEN subsidiary. Total revenue for the third quarter of 1997 was $4.2 million. The decrease in revenue is due primarily to the recording of minimum contractual royalties for Quadramet(R) during the 1997 third quarter, which were in excess of actual sales. ProstaScint sales rose over 30% to $1.6 million compared to $1.2 million in the comparable quarter of 1997. For the third quarter, actual sales of Quadramet were $735,000, compared to the minimum royalty revenue of $1.6 million recorded by CYTOGEN in the same quarter in 1997. License and contract revenues for the third quarter of 1998 were $210,000, compared to $1.0 million for the third quarter of 1997, due to a reduction in contract research work in 1998. Jim